Intratumoral epigenetic plasticity manifests as dynamically shifting methylation landscapes that evade single-timepoint assays clinically evidenced by MGMT promoter reversion in 37% of recurrent glioblastoma patients [150]. This evidence concerns the gene MGMT and glioblastoma.